MIN-117 explained
MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[1] [2] [3] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4] [5] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD. In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.[6]
See also
External links
Notes and References
- Web site: Minerva Neuroscience . 2015-05-19.
- Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates . Minerva Neurosciences . GlobalNewswire . 2015 . 2015-05-19.
- Web site: Investor Presentation March 2015 . Minerva Neurosciences . 2015-05-19 . dead . https://web.archive.org/web/20150520033706/http://files.shareholder.com/downloads/AMDA-2MIFBM/0x0x813311/13B96B22-1D5F-470D-888B-8E1F47FE6AFA/Minerva_Investor_Presentation_-_March_2015.pdf . 2015-05-20 .
- Web site: Company Profile for Minerva Neurosciences Inc. . Reuters . https://web.archive.org/web/20150520163323/http://in.reuters.com/finance/stocks/companyProfile?symbol=NERV.O . dead . 2015-05-20 . 2015-05-19.
- Web site: Some Nerves Surrounding Minerva Neurosciences IPO . Don . Dion . Seeking Alpha . 2014 . 2015-05-19.
- Web site: Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder. 2020-07-28. BioSpace. en-US.
